Metabolic Syndrome

Introduction
Metabolic syndrome stakeholders in the US are very active in online communities - sharing information, experiences, and emotions. This report looks at perceptions of products, treatment regimens, the disease, and quality of life issues as expressed by metabolic syndrome stakeholders in major US online communities and forums.

Scope of This Report

• 173,181 stakeholder opinions from 1170 unique online users
• Volume and quality of overall opinion is reviewed focusing on individual drugs
• Emotional scores are evaluated for each of the key drugs used in the treatment of metabolic syndrome
• Specific stakeholder sentiments are compared across major drugs

Key Highlights

There is a high level of disappointment with current options, indicating a high level of unmet need. Despite this, there is a relatively high level of hopefulness. This disappointment may stem from the lack of a general syndrome product or an effective solution for obesity.
Asthma is a leading co-morbid condition, and is often related to obesity. This is another sign that obesity is actively being avoided as a topic of discussion in the context of metabolic syndrome.
Arrhythmia, myocardial infarction, atrial fibrillation, tachycardia and angina are all mentioned regularly in the context of metabolic syndrome. The negative perceptions of these disorders may be related to the attendant gravity or the lack of perceived control.

Reasons to Purchase

• Identify stakeholders’ perceptions of products, treatment regimens, and their experience with metabolic syndrome.
• Evaluate product performance across a variety of emotional dimensions including perceptions of quality, effectiveness, and brand allegiance.
• Understand current trends in stakeholder thinking and identify patterns that may assist in future product development and launch strategy.